ZA200409639B - Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles - Google Patents
Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles Download PDFInfo
- Publication number
- ZA200409639B ZA200409639B ZA200409639A ZA200409639A ZA200409639B ZA 200409639 B ZA200409639 B ZA 200409639B ZA 200409639 A ZA200409639 A ZA 200409639A ZA 200409639 A ZA200409639 A ZA 200409639A ZA 200409639 B ZA200409639 B ZA 200409639B
- Authority
- ZA
- South Africa
- Prior art keywords
- methoxy
- amino
- quinolinecarbonitrile
- methoxyphenyl
- dichloro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- -1 -Ng Chemical group 0.000 claims description 70
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 12
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Chemical group 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 230000002140 halogenating effect Effects 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- CRDISMZBOJPSJG-UHFFFAOYSA-N 7-fluoroquinoline-3-carbonitrile Chemical compound C1=C(C#N)C=NC2=CC(F)=CC=C21 CRDISMZBOJPSJG-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Chemical group 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- JCGQIVMIQPTWGQ-UHFFFAOYSA-N 7-fluoro-4-oxo-1h-quinoline-3-carbonitrile Chemical compound FC1=CC=C2C(O)=C(C#N)C=NC2=C1 JCGQIVMIQPTWGQ-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 claims description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical group ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 2
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- DDUAWKDPAINNCL-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-(2-methoxyethoxy)-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OCCOC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl DDUAWKDPAINNCL-UHFFFAOYSA-N 0.000 claims 1
- ZVETWCRMSCEEOV-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-(2-methoxyethoxy)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCOC)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl ZVETWCRMSCEEOV-UHFFFAOYSA-N 0.000 claims 1
- RFMNZXCDCPAELC-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(2-methoxyethoxy)quinoline-3-carbonitrile Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NC=C(C#N)C=1NC1=CC(OC)=C(Cl)C=C1Cl RFMNZXCDCPAELC-UHFFFAOYSA-N 0.000 claims 1
- HBULUYHVBOFATD-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(2-methoxyethylamino)quinoline-3-carbonitrile Chemical compound C=12C=C(OC)C(NCCOC)=CC2=NC=C(C#N)C=1NC1=CC(OC)=C(Cl)C=C1Cl HBULUYHVBOFATD-UHFFFAOYSA-N 0.000 claims 1
- QIOJDBXGJHGPKE-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(oxan-2-ylmethoxy)quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC4OCCCC4)C=C3N=CC=2C#N)=C1Cl QIOJDBXGJHGPKE-UHFFFAOYSA-N 0.000 claims 1
- AEKLMFMMEQCHJM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(piperidin-4-ylmethoxy)quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC4CCNCC4)C=C3N=CC=2C#N)=C1Cl AEKLMFMMEQCHJM-UHFFFAOYSA-N 0.000 claims 1
- NWWCMWNHYATVKP-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-(thiophen-2-ylmethoxy)quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC=4SC=CC=4)C=C3N=CC=2C#N)=C1Cl NWWCMWNHYATVKP-UHFFFAOYSA-N 0.000 claims 1
- QSBWHISTPSABIV-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[(1-methylpiperidin-2-yl)methoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC4N(CCCC4)C)C=C3N=CC=2C#N)=C1Cl QSBWHISTPSABIV-UHFFFAOYSA-N 0.000 claims 1
- FCIILWHQWNLPJU-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl FCIILWHQWNLPJU-UHFFFAOYSA-N 0.000 claims 1
- FFLOUGHZSSJEFD-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(2-piperazin-1-ylethoxy)ethoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCOCCN4CCNCC4)C=C3N=CC=2C#N)=C1Cl FFLOUGHZSSJEFD-UHFFFAOYSA-N 0.000 claims 1
- QXWCRBMAGJJKTO-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl QXWCRBMAGJJKTO-UHFFFAOYSA-N 0.000 claims 1
- DLOUCROPDZBOQC-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-phenylmethoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC=4C=CC=CC=4)C=C3N=CC=2C#N)=C1Cl DLOUCROPDZBOQC-UHFFFAOYSA-N 0.000 claims 1
- OVQDNLYTOCIGFW-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-phenylsulfanylquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(SC=4C=CC=CC=4)C=C3N=CC=2C#N)=C1Cl OVQDNLYTOCIGFW-UHFFFAOYSA-N 0.000 claims 1
- BEUXTQYZIMODSJ-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-pyridin-4-yloxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OC=4C=CN=CC=4)C=C3N=CC=2C#N)=C1Cl BEUXTQYZIMODSJ-UHFFFAOYSA-N 0.000 claims 1
- FESHZTMVVAMERP-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-(2-methoxyethoxy)-6-(2-morpholin-4-ylethoxy)quinoline-3-carbonitrile Chemical compound C=12C=C(OCCN3CCOCC3)C(OCCOC)=CC2=NC=C(C#N)C=1NC1=CC(OC)=C(Cl)C=C1Cl FESHZTMVVAMERP-UHFFFAOYSA-N 0.000 claims 1
- ZTJQAMXVMUEKRE-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile Chemical compound N#CC=1C=NC2=CC(OCCOC)=CC=C2C=1NC1=CC(OC)=C(Cl)C=C1Cl ZTJQAMXVMUEKRE-UHFFFAOYSA-N 0.000 claims 1
- KBRVPVKJZSCXJQ-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC=C(OCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl KBRVPVKJZSCXJQ-UHFFFAOYSA-N 0.000 claims 1
- VLKTYOWJLFRVEM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[3-(dimethylamino)-2,2-dimethylpropoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC(C)(C)CN(C)C)C=C3N=CC=2C#N)=C1Cl VLKTYOWJLFRVEM-UHFFFAOYSA-N 0.000 claims 1
- DRGIDSKCLYYECH-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-ethylsulfanyl-6-methoxyquinoline-3-carbonitrile Chemical compound C=12C=C(OC)C(SCC)=CC2=NC=C(C#N)C=1NC1=CC(OC)=C(Cl)C=C1Cl DRGIDSKCLYYECH-UHFFFAOYSA-N 0.000 claims 1
- ONVKFNZGEFTWQD-UHFFFAOYSA-N 4-(2,4-dichloroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1Cl ONVKFNZGEFTWQD-UHFFFAOYSA-N 0.000 claims 1
- YLCRSZCRMIQCBE-UHFFFAOYSA-N 4-(2,4-dichloroanilino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile Chemical compound N#CC=1C=NC2=CC(OCCOC)=CC=C2C=1NC1=CC=C(Cl)C=C1Cl YLCRSZCRMIQCBE-UHFFFAOYSA-N 0.000 claims 1
- OIDVGENURIIFNK-UHFFFAOYSA-N 4-(butylamino)-6-methoxy-7-(2-methoxyethoxy)quinoline-3-carbonitrile Chemical compound COCCOC1=C(OC)C=C2C(NCCCC)=C(C#N)C=NC2=C1 OIDVGENURIIFNK-UHFFFAOYSA-N 0.000 claims 1
- CQXPBXPRKLSEQU-UHFFFAOYSA-N 4-(cyclopentylamino)-6-methoxy-7-(2-methoxyethoxy)quinoline-3-carbonitrile Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NC=C(C#N)C=1NC1CCCC1 CQXPBXPRKLSEQU-UHFFFAOYSA-N 0.000 claims 1
- IDZGVCCTBGKTHH-UHFFFAOYSA-N 4-[3-chloro-4-(1-methylimidazol-2-yl)sulfanylanilino]-6-methoxy-7-(4-methylpiperazin-1-yl)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(N3CCN(C)CC3)C(OC)=CC2=C1NC(C=C1Cl)=CC=C1SC1=NC=CN1C IDZGVCCTBGKTHH-UHFFFAOYSA-N 0.000 claims 1
- MVFPMLNUGKMXGV-UHFFFAOYSA-N 4-[3-chloro-4-(1-methylimidazol-2-yl)sulfanylanilino]-7-[3-(dimethylamino)propoxy]-6-(2-methoxyethoxy)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN(C)C)C(OCCOC)=CC2=C1NC(C=C1Cl)=CC=C1SC1=NC=CN1C MVFPMLNUGKMXGV-UHFFFAOYSA-N 0.000 claims 1
- HNQAZVSIDPRVTH-UHFFFAOYSA-N 4-[3-chloro-4-(1-methylimidazol-2-yl)sulfanylanilino]-7-[3-(dimethylamino)propyl-methylamino]-6-methoxyquinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(N(C)CCCN(C)C)C(OC)=CC2=C1NC(C=C1Cl)=CC=C1SC1=NC=CN1C HNQAZVSIDPRVTH-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- VFYULBSOWVNOGO-UHFFFAOYSA-N 6-butoxy-4-(2,4-dichloro-5-methoxyanilino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCOC)C(OCCCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl VFYULBSOWVNOGO-UHFFFAOYSA-N 0.000 claims 1
- CEWSFUURKWZZLP-UHFFFAOYSA-N 6-methoxy-7-(2-methoxyethoxy)-4-(3,4,5-trimethoxyanilino)quinoline-3-carbonitrile Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NC=C(C#N)C=1NC1=CC(OC)=C(OC)C(OC)=C1 CEWSFUURKWZZLP-UHFFFAOYSA-N 0.000 claims 1
- ZQIKKTDSYYSDKY-UHFFFAOYSA-N 6-methoxy-7-(2-methoxyethoxy)-4-(5-methoxy-2-methylanilino)quinoline-3-carbonitrile Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NC=C(C#N)C=1NC1=CC(OC)=CC=C1C ZQIKKTDSYYSDKY-UHFFFAOYSA-N 0.000 claims 1
- BRQIOABUVVYKGF-UHFFFAOYSA-N 6-methoxy-7-(2-methoxyethoxy)-4-oxo-1h-quinoline-3-carbonitrile Chemical compound C1=C(C#N)C(O)=C2C=C(OC)C(OCCOC)=CC2=N1 BRQIOABUVVYKGF-UHFFFAOYSA-N 0.000 claims 1
- PBFJUQMKCXCVFE-UHFFFAOYSA-N 6-methoxy-7-(4-methylpiperazin-1-yl)-4-(4-phenoxyanilino)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(N3CCN(C)CC3)C(OC)=CC2=C1NC(C=C1)=CC=C1OC1=CC=CC=C1 PBFJUQMKCXCVFE-UHFFFAOYSA-N 0.000 claims 1
- WOLFNNDNYZSNGW-UHFFFAOYSA-N 6-methoxy-7-(4-methylpiperazin-1-yl)-4-oxo-1h-quinoline-3-carbonitrile Chemical compound COC1=CC(C(C(C#N)=CN2)=O)=C2C=C1N1CCN(C)CC1 WOLFNNDNYZSNGW-UHFFFAOYSA-N 0.000 claims 1
- BWLSIYJKVFXNFV-UHFFFAOYSA-N 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(3,4,5-trimethoxyanilino)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OC)=CC2=C1NC1=CC(OC)=C(OC)C(OC)=C1 BWLSIYJKVFXNFV-UHFFFAOYSA-N 0.000 claims 1
- SFDZUJYVIBHPBB-UHFFFAOYSA-N 7-(2-methoxyethoxy)-4-oxo-1h-quinoline-3-carbonitrile Chemical compound N1C=C(C#N)C(=O)C=2C1=CC(OCCOC)=CC=2 SFDZUJYVIBHPBB-UHFFFAOYSA-N 0.000 claims 1
- XVORGNWOJRXXOM-UHFFFAOYSA-N 7-benzylsulfanyl-4-(2,4-dichloro-5-methoxyanilino)-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(SCC=4C=CC=CC=4)C=C3N=CC=2C#N)=C1Cl XVORGNWOJRXXOM-UHFFFAOYSA-N 0.000 claims 1
- IVOKHHAKFXNCRK-UHFFFAOYSA-N 7-but-2-ynoxy-4-(2,4-dichloro-5-methoxyanilino)-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC#CC)C=C3N=CC=2C#N)=C1Cl IVOKHHAKFXNCRK-UHFFFAOYSA-N 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 239000000543 intermediate Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37645602P | 2002-04-30 | 2002-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200409639B true ZA200409639B (en) | 2006-06-28 |
Family
ID=29401349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200409639A ZA200409639B (en) | 2002-04-30 | 2004-11-29 | Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles |
Country Status (27)
Country | Link |
---|---|
US (1) | US6780996B2 (xx) |
EP (1) | EP1499594B1 (xx) |
JP (1) | JP2005529907A (xx) |
KR (1) | KR20040106420A (xx) |
CN (1) | CN100354263C (xx) |
AR (1) | AR039776A1 (xx) |
AT (1) | ATE302191T1 (xx) |
AU (1) | AU2003231162B2 (xx) |
BR (1) | BR0309712A (xx) |
CA (1) | CA2483529A1 (xx) |
CO (1) | CO5631435A2 (xx) |
CR (1) | CR7511A (xx) |
DE (1) | DE60301350T2 (xx) |
DK (1) | DK1499594T3 (xx) |
EC (1) | ECSP045406A (xx) |
ES (1) | ES2243903T3 (xx) |
HK (1) | HK1070358A1 (xx) |
IL (1) | IL164851A0 (xx) |
MX (1) | MXPA04010664A (xx) |
NO (1) | NO20044533L (xx) |
NZ (1) | NZ536141A (xx) |
RU (1) | RU2309149C2 (xx) |
SI (1) | SI1499594T1 (xx) |
TW (1) | TWI275390B (xx) |
UA (1) | UA77799C2 (xx) |
WO (1) | WO2003093241A1 (xx) |
ZA (1) | ZA200409639B (xx) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2500368A1 (en) * | 2002-10-04 | 2004-04-22 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
TW200423938A (en) * | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
MXPA06004744A (es) * | 2003-11-06 | 2006-07-05 | Wyeth Corp | 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica. |
FR2862301B1 (fr) * | 2003-11-17 | 2007-12-21 | Aventis Pharma Sa | Nouveau procede de preparation de quinoleines 3-fluorees |
TW200529846A (en) * | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
MX2007004833A (es) * | 2004-10-22 | 2007-05-16 | Wyeth Corp | 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolin ocarbonitrilos para el tratamiento de lesion isquemica. |
CN101155579B (zh) | 2005-02-03 | 2012-10-31 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
BRPI0609928A2 (pt) * | 2005-05-18 | 2010-05-11 | Wyeth Corp | inibidores de quinase tpl-2 de 3-cianoquinolina e métodos de fabricação e uso dos mesmos |
BRPI0613146B8 (pt) | 2005-06-17 | 2021-05-25 | Univ Texas | uso terapêutico de inibidores de src quinase |
RU2007148072A (ru) | 2005-07-01 | 2009-08-10 | Вайет (Us) | Кристаллические формы 4-[(2,4-дихлор-5-метоксифинил)амино]-6- меокси-7-[3-(4-метил-1-пиперазинил)пропокси]-3-хиналинкарбонитрил и способы их получения |
CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
TW200808728A (en) * | 2006-05-23 | 2008-02-16 | Wyeth Corp | Method of preparing 4-halogenated quinoline intermediates |
WO2008060283A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
EP3002009B1 (en) | 2007-06-01 | 2021-07-07 | Wyeth LLC | Treatment of imatinib resistant chronic myelogenous leukemia having the mutaton 1457t>c in the bcrabl gene using the compound bosutinib |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
CN101602687A (zh) * | 2008-06-13 | 2009-12-16 | 上海特化医药科技有限公司 | 6-硝基苯乙酮类化合物、其制备方法及用途 |
KR20130088908A (ko) | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
CN109464445A (zh) * | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
WO2010030835A2 (en) * | 2008-09-11 | 2010-03-18 | Wyeth Llc | Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor |
CN101723854A (zh) | 2008-10-24 | 2010-06-09 | 上海特化医药科技有限公司 | 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体 |
ES2941894T3 (es) | 2009-04-06 | 2023-05-26 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
RU2600928C2 (ru) * | 2010-06-09 | 2016-10-27 | Тяньцзинь Химэй Байо-Тек Ко., Лтд | Цианохинолиновые производные |
CN103261186A (zh) | 2010-12-13 | 2013-08-21 | 诺瓦提斯公司 | 二聚化iap抑制剂 |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
CN103857288B (zh) | 2011-03-04 | 2016-09-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的氨基-喹啉 |
US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
WO2013012723A1 (en) | 2011-07-13 | 2013-01-24 | Novartis Ag | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
AU2012282076A1 (en) | 2011-07-13 | 2014-02-27 | Novartis Ag | 4 - piperidinyl compounds for use as tankyrase inhibitors |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
JP6158833B2 (ja) | 2012-01-09 | 2017-07-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | ベータ−カテニン関連疾患を処置するための有機組成物 |
AR092530A1 (es) * | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
CN103804353A (zh) * | 2012-11-01 | 2014-05-21 | 常辉 | 一类治疗精神分裂症的化合物及其用途 |
JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
SI2958907T1 (en) | 2013-02-19 | 2018-05-31 | Novartis Ag | Benzothiophene derivatives and their compositions as selective estrogen receptor antagonists |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
AR094707A1 (es) | 2013-02-21 | 2015-08-19 | Glaxosmithkline Ip Dev Ltd | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
AP2015008656A0 (en) | 2013-03-15 | 2015-08-31 | Novartis Ag | Antibody drug conjugates |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN106061261B (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
EP2980088A1 (en) | 2014-07-28 | 2016-02-03 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
IN2014CH00840A (xx) * | 2014-02-20 | 2015-09-18 | Apotex Inc | |
WO2015149727A1 (en) | 2014-04-02 | 2015-10-08 | Zentiva, K.S. | Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
MX2017001946A (es) | 2014-08-12 | 2017-06-19 | Novartis Ag | Conjugados de farmacos con anticuerpos anti-cdh6. |
WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
EP3200775B1 (en) | 2014-10-03 | 2019-11-20 | Novartis AG | Combination therapies |
KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
CN104311485B (zh) * | 2014-10-13 | 2016-08-24 | 烟台市华文欣欣医药科技有限公司 | 一种治疗白血病的药物博舒替尼的制备方法 |
AU2015347015B2 (en) | 2014-11-14 | 2019-02-14 | Novartis Ag | Antibody drug conjugates |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
EP3789027A1 (en) | 2015-01-13 | 2021-03-10 | Kyoto University | Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis |
AU2016238436A1 (en) | 2015-03-25 | 2017-08-17 | Novartis Ag | Formylated N-heterocyclic derivatives as FGFR4 inhibitors |
CA2982996A1 (en) | 2015-04-17 | 2016-10-20 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物および組成物 |
CN108780084B (zh) | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
CN105085398A (zh) * | 2015-09-06 | 2015-11-25 | 合肥华方医药科技有限公司 | 一种博舒替尼异构体杂质的制备方法 |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
US10577362B2 (en) | 2016-05-04 | 2020-03-03 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
US10934285B2 (en) | 2016-06-14 | 2021-03-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
CN117866991A (zh) | 2016-10-07 | 2024-04-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
EP3630813A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
EP3630162A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
CN111201223B (zh) | 2017-09-11 | 2024-07-09 | 克鲁松制药公司 | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
FI3820573T3 (fi) | 2018-07-10 | 2023-11-01 | Novartis Ag | 3-(5-hydroksi-1-oksoisoindolin-2-yyli)piperidiini-2,6-dionijohdannaisia ja niiden käyttö ikaros-perheen sinkkisormi 2 (ikzf2) -riippuvaisten sairauksien hoidossa |
WO2020021322A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
MX2021003158A (es) | 2018-09-18 | 2021-07-16 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2. |
US20220041613A1 (en) | 2018-09-25 | 2022-02-10 | Black Diamond Therapeutics, Inc. | Tyrosine kinase inhibitor compositions, methods of making and methods of use |
CN113382986A (zh) | 2018-09-25 | 2021-09-10 | 黑钻治疗公司 | 酪氨酸激酶抑制剂组合物、其制备方法和使用方法 |
CN117122707A (zh) | 2018-09-25 | 2023-11-28 | 意大利国际先进加速器应用有限公司 | 联合疗法 |
KR20210068473A (ko) | 2018-09-29 | 2021-06-09 | 노파르티스 아게 | Shp2 활성 억제용 화합물의 제조 방법 |
EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
JOP20210159A1 (ar) | 2018-12-21 | 2023-01-30 | Novartis Ag | أجسام مضادة لـ pmel17 ومترافقات منها |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
US20220257698A1 (en) | 2019-08-02 | 2022-08-18 | Lanthiopep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
BR112022002518A2 (pt) | 2019-08-15 | 2022-07-19 | Black Diamond Therapeutics Inc | Compostos de alquinila quinazolina |
MX2022005219A (es) | 2019-11-01 | 2022-06-08 | Syngenta Crop Protection Ag | Compuestos heteroaromaticos biciclicos condensados activos como pesticidas. |
CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
IL303661A (en) | 2020-12-22 | 2023-08-01 | Nikang Therapeutics Inc | COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY |
AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
WO2022219407A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2022219412A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
WO2022221720A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2022268648A1 (en) | 2021-06-24 | 2022-12-29 | Syngenta Crop Protection Ag | 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides |
WO2023284730A1 (en) | 2021-07-14 | 2023-01-19 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
WO2023192801A1 (en) | 2022-03-28 | 2023-10-05 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
WO2023247360A1 (en) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
CN115286573A (zh) * | 2022-08-04 | 2022-11-04 | 常州工程职业技术学院 | 一种1-烷氧基异喹啉化合物的绿色合成方法 |
WO2024102849A1 (en) | 2022-11-11 | 2024-05-16 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9756B (en) * | 1996-01-16 | 1997-07-17 | Warner Lambert Co | Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines |
UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
ES2457396T3 (es) | 1998-09-29 | 2014-04-25 | Wyeth Holdings Llc | 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas |
US6638929B2 (en) * | 1999-12-29 | 2003-10-28 | Wyeth | Tricyclic protein kinase inhibitors |
AR035851A1 (es) * | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
DE10017539A1 (de) | 2000-04-08 | 2001-10-11 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US7501516B2 (en) * | 2001-07-16 | 2009-03-10 | Astrazeneca Ab | Quinoline derivatives and their use as tyrosine kinase inhibitors |
-
2003
- 2003-04-28 TW TW092109893A patent/TWI275390B/zh not_active IP Right Cessation
- 2003-04-29 ES ES03724293T patent/ES2243903T3/es not_active Expired - Lifetime
- 2003-04-29 CN CNB038152010A patent/CN100354263C/zh not_active Expired - Fee Related
- 2003-04-29 SI SI200330083T patent/SI1499594T1/sl unknown
- 2003-04-29 DE DE60301350T patent/DE60301350T2/de not_active Expired - Fee Related
- 2003-04-29 RU RU2004134735/04A patent/RU2309149C2/ru active
- 2003-04-29 KR KR10-2004-7017459A patent/KR20040106420A/ko not_active Application Discontinuation
- 2003-04-29 JP JP2004501380A patent/JP2005529907A/ja not_active Withdrawn
- 2003-04-29 EP EP03724293A patent/EP1499594B1/en not_active Expired - Lifetime
- 2003-04-29 BR BR0309712-9A patent/BR0309712A/pt not_active IP Right Cessation
- 2003-04-29 UA UA20041109740A patent/UA77799C2/uk unknown
- 2003-04-29 CA CA002483529A patent/CA2483529A1/en not_active Withdrawn
- 2003-04-29 IL IL16485103A patent/IL164851A0/xx unknown
- 2003-04-29 NZ NZ536141A patent/NZ536141A/xx unknown
- 2003-04-29 AR ARP030101486A patent/AR039776A1/es unknown
- 2003-04-29 WO PCT/US2003/013149 patent/WO2003093241A1/en active IP Right Grant
- 2003-04-29 US US10/425,765 patent/US6780996B2/en not_active Expired - Fee Related
- 2003-04-29 DK DK03724293T patent/DK1499594T3/da active
- 2003-04-29 MX MXPA04010664A patent/MXPA04010664A/es active IP Right Grant
- 2003-04-29 AU AU2003231162A patent/AU2003231162B2/en not_active Withdrawn - After Issue
- 2003-04-29 AT AT03724293T patent/ATE302191T1/de not_active IP Right Cessation
-
2004
- 2004-10-06 CR CR7511A patent/CR7511A/es unknown
- 2004-10-21 NO NO20044533A patent/NO20044533L/no not_active Application Discontinuation
- 2004-10-28 CO CO04108774A patent/CO5631435A2/es not_active Application Discontinuation
- 2004-10-29 EC EC2004005406A patent/ECSP045406A/es unknown
- 2004-11-29 ZA ZA200409639A patent/ZA200409639B/en unknown
-
2005
- 2005-04-08 HK HK05103003A patent/HK1070358A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200409639B (en) | Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles | |
EP3203840A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
JP2013537183A (ja) | キナーゼインヒビターとしてのキノリン及びキノキサリン誘導体 | |
KR20020063934A (ko) | 코르티코트로핀 방출 인자 길항제 | |
CN102432552B (zh) | 作为受体酪氨酸激酶抑制剂的喹唑啉类似物 | |
JP2005533803A5 (xx) | ||
EP2597955A1 (en) | Quinoline derivatives and melk inhibitors containing the same | |
IL105806A (en) | History of aminoquinoline and pharmaceuticals containing them | |
CZ20013997A3 (cs) | Chinolinové deriváty jako inhibitory MEK enzymů | |
JP2002544195A (ja) | Mek酵素の阻害薬としてのキノリン誘導体 | |
JP2013521265A (ja) | 薬物製造のためのイソキノロン類の使用、新規なイソキノロン類およびそれらの合成方法 | |
EP0878194A1 (en) | Remedies or preventives for aids | |
WO2018214814A1 (zh) | 氨基亚甲基环己烷1,3-二酮化合物的用途 | |
HUT76643A (en) | Trifluoromethylquinolinecarboxylic acid derivative, pharmaceutical compositions containing them and their use | |
TW200404067A (en) | New compounds | |
CN116134022A (zh) | Atr抑制剂和其用途 | |
JPH08183775A (ja) | トリフルオロメチルキノリンカルボン酸誘導体 | |
WO1997032854A1 (fr) | Derives de 2-sulfinylnicotinamide, intermediaire de ces derives, procede pour produire ces derives et composition medicinale contenant ces derives comme ingredient actif | |
US20090099356A1 (en) | Preparation of 7-alkenyl-3 quinolinecarbonitriles via a palladium mediated coupling reaction | |
CA2293480A1 (en) | 2-aminoalkylaminoquinolines as dopamine d4 ligands | |
US20040158066A1 (en) | Novel pyridylmethylaminopyrimidines | |
WO1999042106A1 (fr) | Agent anti-hcmv | |
KR20050019800A (ko) | 아미드 유도체 | |
AU2002314064A1 (en) | Novel pyridylmethylaminopyrimidines |